Vertex Pharmaceutica
Delayed Nasdaq - 05/25 10:00:00 pm

Vertex Pharmaceuticals : Breakfast Technical Briefing on Biotech Stocks -- Sarepta Therapeutics, Trevena, Tesaro, and Vertex Pharma

Envoyer par e-mail
08/07/2017 | 12:10 pm

NEW YORK, August 7, 2017 /PRNewswire/ --

If you want a Stock Review on SRPT, TRVN, TSRO, or VRTX then come over to and sign up for your free customized report
today. has issued research reports on Sarepta Therapeutics Inc.
(NASDAQ: SRPT), Trevena Inc. (NASDAQ: TRVN), Tesaro Inc. (NASDAQ: TSRO), and Vertex
Pharmaceuticals Inc. (NASDAQ: VRTX). According to a report on PR Newswire, Biotech and Big
Pharma companies are in the spotlight these days, evidenced by the dramatic shift in the
NASDAQ Biotechnology Index increasing by as much as 33% after hitting new highs in July.
Daily Stock Tracker published free research reports on these stocks today at:

Sarepta Therapeutics 

Cambridge, Massachusetts headquartered Sarepta Therapeutics Inc.'s stock rose 1.69%,
finishing last Friday's trading session at $38.52. A total volume of 1.50 million shares
was traded. The Company's shares have gained 13.09% in the last month, 17.98% over the
previous three months, and 40.43% since the start of this year. The stock is trading above
its 50-day and 200-day moving averages by 10.78% and 14.33%, respectively. Additionally,
shares of Sarepta Therapeutics, which focuses on the discovery and development of
RNA-based therapeutics for the treatment of rare neuromuscular diseases, have a Relative
Strength Index (RSI) of 54.83.

On July 20th, 2017, research firm RBC Capital Markets reiterated its 'Outperform'
rating on the Company's stock with an increase of the target price from $60 a share to $64
a share.

On July 27th, 2017, Sarepta Therapeutics announced the publication of data validating
Genethon's micro-dystrophin gene therapy approach in an animal model for Duchenne muscular
dystrophy (DMD). The results were featured in the July 25th, 2017 online issue of Nature
Communications. The Company announced in June 2017 that it entered into exclusive gene
therapy research collaboration with Genethon to jointly develop treatments for DMD. See
our free and comprehensive research report on SRPT at:


Shares in King of Prussia, Pennsylvania headquartered Trevena Inc. ended at $2.43,
jumping 4.74% from the last trading session. The stock recorded a trading volume of
426,384 shares. The Company's shares have advanced 5.65% in the past month. The stock is
trading 4.90% below its 50-day moving average. Moreover, shares of Trevena, which develops
various therapies based on breakthrough science to benefit patients and healthcare
providers confronting serious medical conditions, have an RSI of 43.73.

On August 03rd, 2017, Trevena announced financial results for the quarter ended June
30th, 2017. Net loss for Q2 2017 was $20.4 million; research and development expenses were
$15.5 million; and general and administrative expenses were $4.4 million. Cash, cash
equivalents, and marketable securities were $84.2 million as of June 30th, 2017. TRVN free
research report is just a click away at:


On Friday, shares in Waltham, Massachusetts headquartered Tesaro Inc. recorded a
trading volume of 711,508 shares. The stock climbed 3.24%, closing the day at $128.59. The
Company's shares are trading 6.80% below their 50-day moving average. Additionally, shares
of Tesaro, which identifies, acquires, develops, and commercializes cancer therapeutics
and oncology supportive care products in the US, have an RSI of 47.58.  

On July 07th, 2017, research firm Gabelli & Co initiated a 'Buy' rating on the
Company's stock, with a target price of $175 per share.

On July 25th, 2017, Tesaro announced that the Company will release its Q2 2017
financial results on August 08th, 2017, after the close of the US financial markets. The
senior management team will host a conference call and live audio webcast at 4:15 p.m. ET
on that same day to discuss the Company's operating results in greater detail, as well as
the status of its development programs and the VARUBI/Y(R) and ZEJULATM launches. Sign up
for your complimentary report on TSRO at:

Vertex Pharma 

At the close of trading on Friday, shares in Boston, Massachusetts headquartered
Vertex Pharmaceuticals Inc. recorded a trading volume of 806,212 shares. The stock
finished the session 0.33% higher at $154.54. The Company's shares have surged 20.30% in
the past month, 34.57% in the previous three months, and 109.77% since the start of this
year. The stock is trading above its 50-day and 200-day moving averages by 14.59% and
50.18%, respectively. Furthermore, shares of Vertex Pharma, which discovers, develops,
manufactures, and commercializes medicines for serious diseases, have an RSI of 60.25.

On July 19th, 2017, research firm Raymond James upgraded the Company's stock rating
from 'Market Perform' to 'Outperform'.

On July 26th, 2017, Vertex Pharma reported consolidated financial results for the
second quarter ended June 30th, 2017. Total CF net product revenues were $514.0 million
for the quarter, net product revenues from ORKAMBI were $324.4 million, and net product
revenues from KALYDECO were $189.6 million. As of June 30th, 2017, the Company had $1.67
billion in cash, cash equivalents and marketable securities. Register for free on and download the latest research report on VRTX at:


Daily Stock Tracker: 

Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports,
articles, stock market blogs, and popular investment newsletters covering equities listed
on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments.
One department produces non-sponsored analyst certified content generally in the form of
press releases, articles and reports covering equities listed on NYSE and NASDAQ and the
other produces sponsored content (in most cases not reviewed by a registered analyst),
which typically consists of compensated investment newsletters, articles and reports
covering listed stocks and micro-caps. Such sponsored content is outside the scope of
procedures detailed below. 

DST has not been compensated; directly or indirectly; for producing or publishing this


The non-sponsored content contained herein has been prepared by a writer (the "Author")
and is fact checked and reviewed by a third party research service company (the
"Reviewer") represented by a credentialed financial analyst [for further information on
analyst credentials, please email [email protected] Rohit Tuli, a CFA(R)
charterholder (the "Sponsor"), provides necessary guidance in preparing the document
templates. The Reviewer has reviewed and revised the content, as necessary, based on
publicly available information which is believed to be reliable. Content is researched,
written and reviewed on a reasonable-effort basis. The Reviewer has not performed any
independent investigations or forensic audits to validate the information herein. The
Reviewer has only independently reviewed the information provided by the Author according
to the procedures outlined by DST. DST is not entitled to veto or interfere in the
application of such procedures by the third-party research service company to the articles,
documents or reports, as the case may be. Unless otherwise noted, any content outside of
this document has no association with the Author or the Reviewer in any way.  


DST, the Author, and the Reviewer are not responsible for any error which may be
occasioned at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted whatsoever for any direct, indirect or consequential loss arising
from the use of this document. DST, the Author, and the Reviewer expressly disclaim any
fiduciary responsibility or liability for any consequences, financial or otherwise arising
from any reliance placed on the information in this document. Additionally, DST, the
Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or
correct sequencing of the information, or (2) warrant any results from use of the
information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an
offer to buy or sell the securities mentioned or discussed, and is to be used for
informational purposes only. Please read all associated disclosures and disclaimers in
full before investing. Neither DST nor any party affiliated with us is a registered
investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To
download our report(s), read our disclosures, or for more information, visit

For any questions, inquiries, or comments reach out to us directly. If you're a company
we are covering and wish to no longer feature on our coverage list contact us via
email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: [email protected]
Phone number: (207)331-3313
Office Address: 377 Rivonia Boulevard, Rivonia, South Africa


CFA(R) and Chartered Financial Analyst(R) are registered trademarks owned by CFA

SOURCE Chelmsford Park SA

PRNewswire 2018
Envoyer par e-mail